BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 30652951)

  • 1. Hybrid quantum dot-based theranostic nanomedicines for tumor-targeted drug delivery and cancer imaging.
    Zayed DG; AbdElhamid AS; Freag MS; Elzoghby AO
    Nanomedicine (Lond); 2019 Feb; 14(3):225-228. PubMed ID: 30652951
    [No Abstract]   [Full Text] [Related]  

  • 2. Hybrid protein-inorganic nanoparticles: From tumor-targeted drug delivery to cancer imaging.
    Elzoghby AO; Hemasa AL; Freag MS
    J Control Release; 2016 Dec; 243():303-322. PubMed ID: 27794493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oligonucleotide-based theranostic nanoparticles in cancer therapy.
    Shahbazi R; Ozpolat B; Ulubayram K
    Nanomedicine (Lond); 2016 May; 11(10):1287-308. PubMed ID: 27102380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prussian blue nanoparticles and their analogues for application to cancer theranostics.
    Patra CR
    Nanomedicine (Lond); 2016 Mar; 11(6):569-72. PubMed ID: 26911239
    [No Abstract]   [Full Text] [Related]  

  • 5. Immune Cell-Mediated Biodegradable Theranostic Nanoparticles for Melanoma Targeting and Drug Delivery.
    Xie Z; Su Y; Kim GB; Selvi E; Ma C; Aragon-Sanabria V; Hsieh JT; Dong C; Yang J
    Small; 2017 Mar; 13(10):. PubMed ID: 28026115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chondroitin sulfate derived theranostic nanoparticles for targeted drug delivery.
    Varghese OP; Liu J; Sundaram K; Hilborn J; Oommen OP
    Biomater Sci; 2016 Aug; 4(9):1310-3. PubMed ID: 27431007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Supramolecular Agents for Theranostics].
    Deyev SM; Lebedenko EN
    Bioorg Khim; 2015; 41(5):539-52. PubMed ID: 26762091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using Peptide Aptamer Targeted Polymers as a Model Nanomedicine for Investigating Drug Distribution in Cancer Nanotheranostics.
    Zhao Y; Houston ZH; Simpson JD; Chen L; Fletcher NL; Fuchs AV; Blakey I; Thurecht KJ
    Mol Pharm; 2017 Oct; 14(10):3539-3549. PubMed ID: 28880092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive approach of hybrid nanoplatforms in drug delivery and theranostics to combat cancer.
    Thorat ND; Townley HE; Patil RM; Tofail SAM; Bauer J
    Drug Discov Today; 2020 Jul; 25(7):1245-1252. PubMed ID: 32371139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coating microbubbles with nanoparticles for medical imaging and drug delivery.
    Tay LM; Xu C
    Nanomedicine (Lond); 2017 Jan; 12(2):91-94. PubMed ID: 27876447
    [No Abstract]   [Full Text] [Related]  

  • 11. Advances in Functionalized Mesoporous Silica Nanoparticles for Tumor Targeted Drug Delivery and Theranostics.
    Zhang W; Liu M; Liu A; Zhai G
    Curr Pharm Des; 2017; 23(23):3367-3382. PubMed ID: 27784244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell membrane-coated nanocarriers: the emerging targeted delivery system for cancer theranostics.
    Bose RJ; Paulmurugan R; Moon J; Lee SH; Park H
    Drug Discov Today; 2018 Apr; 23(4):891-899. PubMed ID: 29426004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Graphene Quantum Dots for Theranostics and Bioimaging.
    Schroeder KL; Goreham RV; Nann T
    Pharm Res; 2016 Oct; 33(10):2337-57. PubMed ID: 27207272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of polymeric nanoparticle formulations by effective imaging and quantitation of cellular uptake for controlled delivery of doxorubicin.
    Win KY; Teng CP; Ye E; Low M; Han MY
    Small; 2015 Mar; 11(9-10):1197-204. PubMed ID: 25400129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New insight into the engineering of green carbon dots: Possible applications in emerging cancer theranostics.
    Radnia F; Mohajeri N; Zarghami N
    Talanta; 2020 Mar; 209():120547. PubMed ID: 31892009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Luminescent/magnetic PLGA-based hybrid nanocomposites: a smart nanocarrier system for targeted codelivery and dual-modality imaging in cancer theranostics.
    Shen X; Li T; Chen Z; Geng Y; Xie X; Li S; Yang H; Wu C; Liu Y
    Int J Nanomedicine; 2017; 12():4299-4322. PubMed ID: 28652734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-EGFR lipid micellar nanoparticles co-encapsulating quantum dots and paclitaxel for tumor-targeted theranosis.
    Kang SJ; Jeong HY; Kim MW; Jeong IH; Choi MJ; You YM; Im CS; Song IH; Lee TS; Park YS
    Nanoscale; 2018 Nov; 10(41):19338-19350. PubMed ID: 30307008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Turn-on theranostic fluorescent nanoprobe by electrostatic self-assembly of carbon dots with doxorubicin for targeted cancer cell imaging, in vivo hyaluronidase analysis, and targeted drug delivery.
    Gao N; Yang W; Nie H; Gong Y; Jing J; Gao L; Zhang X
    Biosens Bioelectron; 2017 Oct; 96():300-307. PubMed ID: 28511113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-targeted nanomedicines for cancer theranostics.
    Arranja AG; Pathak V; Lammers T; Shi Y
    Pharmacol Res; 2017 Jan; 115():87-95. PubMed ID: 27865762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicolorful Carbon Dots for Tumor Theranostics.
    Wang H; Bi J; Zhu BW; Tan M
    Curr Med Chem; 2018; 25(25):2894-2909. PubMed ID: 28302015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.